Italia markets close in 2 hours

FTSE MIB
32.902,67
+237,46(+0,73%)
Dow Jones
38.435,86
-153,30(-0,40%)
Nasdaq
17.703,93
+15,04(+0,09%)
Nikkei 225
38.102,44
-712,12(-1,83%)
Petrolio
79,02
+0,57(+0,73%)
Bitcoin EUR
61.226,30
-961,80(-1,55%)

NBIX Mar 2025 175.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

6,70

0,00

(0,00%)

In data: 10:42AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat